× Key messages Background Findings Perspectives Expert commentary
Go back | list
format_size dark_mode
icon-previous icon-next

Perspectives

How does this study impact clinical practice?

  • Current options for AD focus on topicals (corticosteroids or calcineurin inhibitors), UV therapies or systemic immunosuppression – but there remains an unmet need for effective and long-lasting treatment.
  • New therapies that target the underlying inflammation will offer personalized treatment options to physicians and their patients.
  • Lebrikizumab, an IL-13 inhibitor, delivered rapid improvements in patient-reported outcomes as early as Day 2, alongside clinical efficacy and disease severity gains.
  • At Week 16, nearly two-thirds of patients treated with the highest dose of lebrikizumab rated their AD as ‘much better’, compared to only one-fifth of placebo-treated patients.